Securing Long-Term Safety Data to Comply with FDA Guidelines

The Pediatric Oncology Branch of the National Cancer Institute (NCI) is initiating a large-scale, long-term follow-up study (NCT02315599) to monitor delayed adverse effects of gene therapies, including anti-CD19 CAR-T cell therapy, in pediatric cancer patients. This is in accordance with the U.S. Food and Drug Administration (FDA)'s guidelines for the development of human gene therapies, aiming to closely monitor the potential for genomic insertion mutations and tumorigenicity of vector-based therapies for at least 15 years. As both short-term efficacy and long-term follow-up safety data are crucial indicators for the market launch and establishment of gene therapies, the NCI's clinical design is expected to become a long-term standard for the industry. Patients will undergo blood tests every three months for one year after treatment, followed by annual check-ups for the next five years, and annual follow-up for the remaining ten years.

High-Difficulty in Demonstrating Cell Activation and Safety in Pediatric Cancer Patients

Pediatric cancer patients have much more active cell division and metabolism than adults, which increases the risk of unpredictable proliferation of genetically modified immune cells in the body. In particular, the expression of replication-competent retroviruses (RCR) or replication-competent lentiviruses (RCL) during CAR-T therapy can cause life-threatening delayed adverse effects. Therefore, the NCI will continuously verify the occurrence of RCR/RCL and T-cell persistence using polymerase chain reaction (PCR) techniques. If the safety of gene therapy in pediatric patients is proven through this follow-up observation, the expansion of gene editing platforms to other pediatric rare diseases, including solid tumors, will be significantly accelerated.

Competitive Landscape and Differentiation in the CD19-Targeted CAR-T Market

The global CAR-T cell therapy market is rapidly growing, with an estimated size of $5.2 billion to $6.1 billion by 2025, and Novartis' Kymriah and Gilead Sciences' Yescarta are leading the market. These commercialized products have also been required by the FDA to undergo 15-year long-term safety monitoring upon approval. The NCI's study is significant in that it provides valuable real-world control data that can be used as a safety benchmark guideline for emerging biotech companies preparing for FDA approval. In particular, CAR-T therapies targeting CD19 carry the risk of chronic adverse effects such as long-term B-cell depletion and hypogammaglobulinemia, so the results of the NCI's follow-up study will be a benchmark for the safety of these therapies.

Clinical and Financial Impact of the Follow-Up Study, Which Will Continue Until 2050

The NCI plans to enroll up to 500 participants in this study and continue the final investigation until August 2050, compiling long-term data. This ultra-long-term cohort study requires significant budget and continuous infrastructure maintenance, making it a public good that can only be implemented by a national research institution like the NCI. From the perspective of global pharmaceutical companies, this study will provide public academic data that can reduce the burden of massive post-marketing monitoring costs, which will have the effect of reducing the R&D risk and business costs of gene therapies in the long term. In addition, if safety is confirmed in the long term, the investment market will place a higher value on the intangible value of gene therapy platform technology, which will serve as a catalyst for lowering the threshold for early investment by venture capital (VC) firms.